Your browser doesn't support javascript.
loading
Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor, Yara L; van de Haar, Joris; van den Berg, José G; van Sandick, Johanna W; Kodach, Liudmila L; van Dieren, Jolanda M; Balduzzi, Sara; Grootscholten, Cecile; IJsselsteijn, Marieke E; Veenhof, Alexander A F A; Hartemink, Koen J; Vollebergh, Marieke A; Jurdi, Adham; Sharma, Shruti; Spickard, Erik; Owers, Emilia C; Bartels-Rutten, Annemarieke; den Hartog, Peggy; de Miranda, Noel F C C; van Leerdam, Monique E; Haanen, John B A G; Schumacher, Ton N; Voest, Emile E; Chalabi, Myriam.
Afiliação
  • Verschoor YL; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • van den Berg JG; Oncode Institute, Amsterdam, the Netherlands.
  • van Sandick JW; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Kodach LL; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • van Dieren JM; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Balduzzi S; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Grootscholten C; Biometrics department, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • IJsselsteijn ME; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Veenhof AAFA; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Hartemink KJ; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Vollebergh MA; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Jurdi A; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Sharma S; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Spickard E; Natera, Inc, Austin, TX, USA.
  • Owers EC; Natera, Inc, Austin, TX, USA.
  • Bartels-Rutten A; Natera, Inc, Austin, TX, USA.
  • den Hartog P; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • de Miranda NFCC; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • van Leerdam ME; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Haanen JBAG; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Schumacher TN; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Voest EE; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Chalabi M; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Nat Med ; 30(5): 1499, 2024 May.
Article em En | MEDLINE | ID: mdl-38448792
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article